
For international consulting company Accenture (NYSE: ACN), 2025 has been a rough year. Shares have provided a total return of approximately -33% as of the September 25 close. This has put the stock at a historically low valuation multiple. In fact, Accenture’s forward price-to-earnings (P/E) ratio of 17x is the lowest it has been in three years. This suggests a strong opportunity for the stock to recover, especially with its GenAI business booming.
However, given market sentiment and the company’s latest earnings, is Accenture truly a value play, or a train to nowhere for now?